All In Biotech

Drug Trial Radar · NCT05716945

The OPTIMISE Study

Optimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

342

Planned (sponsor's estimate)

Start

Jul 29, 2024

Primary completion

Sep 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the preferred method in the past decade. The main advantage of DMEK over previous techniques is a low graft rejection rate (1-2% per year). Despite this, rejection prophylaxis after DMEK follows the same high potency regimen as previous techniques in the first year, and patients are burdened with indefinite immunosuppression. The current project, OPTIMISE, aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. Corticosteroid eye drops are the mainstay of ocular immunomodulatory therapy. Their main side effect is a steroid-induced increase in intraocular pressure (IOP). It manifests in about one-fourth of patients within the first year after surgery and can lead to irreversible optic nerve damage and vision loss. Patients with IOP elevation require additional medications and hospital visits resulting in reduced quality of life and increased costs. The optimal dosing regimen in the first year after DMEK and whether patients may safely stop steroids after one year remains unknown. As a result, protocols in the Netherlands vary considerably from surgeon to surgeon. Patients are potentially over-treated in the short and long-term, resulting in undue burden for the patient and increased costs. Consequently, the Dutch Ophthalmology Society (NOG) identified the optimal short- and long-term immunosuppressive protocol for corneal transplantation as one of its Top 10 knowledge gaps, underscoring relevance for clinical practice. With this work, the investigators expect to address this knowledge gap to the benefit of our patients and society. Objective: The OPTIMISE study aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. The hypothesis of this study is that Fluorometholone 0.1% in the first year and discontinuing medication in the second year is a cost-effective treatment strategy after DMEK. Study design: The design of this study is a randomized, controlled multicentre trial with a duration of 24 months. Study population: The study population will consist of 342 patients aged 21 years or older undergoing DMEK surgery in one eye. Intervention: All patients will receive Descemet's Membrane Endothelial Keratoplasty. Following this procedure, patients will be randomized into the following post-operative regime in two stages: STEP-I (Year 1): Control group: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months. Intervention group: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. STEP-II (Year 2): Control Group: Half the patients in each study arm will use FML 0.1% daily. Intervention Group: Half the patients in each study arm will discontinue steroids. Main study parameters/endpoints: Primary outcomes: Step-I: IOP elevation compared to baseline Step-II: Endothelial cell loss (ECL) in the second year Secondary outcomes are: * Rejection free graft survival. * Patient reported outcome measures. * Incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE) * Structural outcomes including corneal, central macular and retinal nerve fibre layer thicknesses, and optic nerve head imaging.

Conditions

  • Pseudophakic Bullous Keratopathy
  • Fuchs' Endothelial Dystrophy
  • Intraocular Pressure

Interventions

  • Fluorometholone 0.1% Oph SuspDrug

    Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. Year 2: Half the patients in each study arm will use FML 0.1% daily.

  • Dexamethasone 0.1% ophthalmic suspensionDrug

    Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

  • Stop steroidsOther

    Half the patients in each study arm will discontinue steroids.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference of intraocular pressure elevation between the two armsTime frame: Year 1
  2. Difference of endothelial cell loss (ECL) in the second yearTime frame: Year 2

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Gelre Ziekenhuizen

    Apeldoorn, Gelderland, Netherlands · Recruiting

  • Radboud Universitair Medisch Centrum

    Nijmegen, Gelderland, Netherlands · Recruiting

  • Maastricht Universitair Medisch Centrum+

    Maastricht, Limburg, Netherlands · Recruiting

  • Amsterdam Universitair Medisch Centrum

    Amsterdam, North Holland, Netherlands · Recruiting

  • Deventer Ziekenhuis

    Deventer, Overijssel, Netherlands · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Provincie Groningen, Netherlands · Not yet recruiting

  • Leiden Universitair Medisch Centrum

    Leiden, South Holland, Netherlands · Recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Utrecht, Netherlands · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.